Aclaris initiates Phase 2b trial for modzatinib, a dual ITK/JAK3 inhibitor, targeting lichen planus with no approved treatments.
Quiver AI Summary
Aclaris Therapeutics, Inc. announced the initiation of its Phase 2b ALPHA trial to evaluate modzatinib (ATI-2138), a dual inhibitor of ITK and JAK3, as a potential first-in-class oral therapy for moderate-to-severe lichen planus (LP), a chronic inflammatory disease with no FDA-approved treatments. The trial aims to assess the efficacy and safety of modzatinib in patients with oral erosive lichen planus, among other forms, following positive preclinical results and Fast Track Designation from the FDA. Modzatinib's unique mechanism targets multiple pathways involved in LP pathology, potentially improving patient outcomes significantly. The ALPHA trial will include approximately 100 participants and aims to measure various disease activity scores at different time points. Aclaris is optimistic about modzatinib’s potential to address the significant unmet need in the treatment of LP and other immuno-inflammatory diseases.
Potential Positives
- Initiation of the Phase 2b ALPHA trial for modzatinib represents a significant advancement in clinical research for an area with unmet medical need, potentially positioning Aclaris as a leader in treating lichen planus.
- FDA's Fast Track Designation for modzatinib underscores its potential therapeutic value, facilitating faster development and review for a condition that currently has no approved treatments.
- Modzatinib's unique mechanism of action targeting both upstream T-cell receptor signaling and downstream effector cytokine signaling may offer a comprehensive approach to treating lichen planus, setting it apart from other therapies.
- Positive preclinical activity observed in multiple inflammatory disease models enhances the credibility of modzatinib's efficacy and paves the way for its potential application across various immuno-inflammatory disorders.
Potential Negatives
- Potential delays in the expected timeline for top line results from the OLP cohort, anticipated in the second half of 2027, may raise concerns about the company's ability to deliver on its promises in a timely manner.
- The press release highlights the lack of FDA-approved therapies for lichen planus, which may indicate a challenging market and significant risks associated with the development of modzatinib.
- The mention of risks and uncertainties in clinical trials and reliance on third parties could foster skepticism among investors regarding the company’s control over its development pipeline.
FAQ
What is modzatinib's mechanism of action?
Modzatinib acts as a dual inhibitor of ITK and JAK3, targeting key immune pathways in lichen planus pathology.
What is the ALPHA trial for lichen planus?
The ALPHA trial is a Phase 2b study assessing the safety and efficacy of modzatinib in patients with moderate-to-severe lichen planus.
What is the significance of Fast Track Designation for modzatinib?
Fast Track Designation from the FDA expedites modzatinib's development process for severe lichen planus, addressing unmet medical needs.
What are the main symptoms of lichen planus?
Lichen planus can cause painful oral erosions, itchy lesions on the skin, and potential scarring and hair loss.
Who is Aclaris Therapeutics?
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immuno-inflammatory diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACRS Hedge Fund Activity
We have seen 91 institutional investors add shares of $ACRS stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,734,311 shares (+2145.7%) to their portfolio in Q3 2026, for an estimated $35,422,475
- RA CAPITAL MANAGEMENT, L.P. added 5,918,954 shares (+87.0%) to their portfolio in Q2 2026, for an estimated $31,311,266
- BRAIDWELL LP added 2,142,348 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,333,020
- SIREN, L.L.C. added 2,025,000 shares (+inf%) to their portfolio in Q3 2026, for an estimated $10,651,500
- SILVERARC CAPITAL MANAGEMENT, LLC removed 1,707,941 shares (-87.7%) from their portfolio in Q3 2026, for an estimated $8,983,769
- D. E. SHAW & CO., INC. removed 1,682,152 shares (-80.2%) from their portfolio in Q2 2026, for an estimated $8,898,584
- BALYASNY ASSET MANAGEMENT L.P. removed 1,337,858 shares (-39.8%) from their portfolio in Q2 2026, for an estimated $7,077,268
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ACRS Analyst Ratings
Wall Street analysts have issued reports on $ACRS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/30/2026
- Wedbush issued a "Outperform" rating on 10/28/2026
- HC Wainwright & Co. issued a "Buy" rating on 10/28/2026
- LifeSci Capital issued a "Outperform" rating on 06/02/2026
To track analyst ratings and price targets for $ACRS, check out Quiver Quantitative's $ACRS forecast page.
$ACRS Price Targets
Multiple analysts have issued price targets for $ACRS recently. We have seen 4 analysts offer price targets for $ACRS in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Edward Nash from Canaccord Genuity set a target price of $13.0 on 10/30/2026
- Martin Fan from Wedbush set a target price of $8.0 on 10/28/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $16.0 on 10/28/2026
- An analyst from LifeSci Capital set a target price of $13.0 on 06/02/2026
Full Release
- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -
- Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream -
WAYNE, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced initiation of its randomized, double-blind, placebo-controlled Phase 2b A LP HA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP); the first cohort to be enrolled will be patients with oral erosive lichen planus (OLP). The U.S. Food and Drug Administration has granted Fast Track Designation for modzatinib for moderate-to-severe LP.
LP is a chronic, CD8 cytotoxic T cell-driven inflammatory disease that can cause painful oral erosions, permanent scarring hair loss, and genital lesions, and is associated with a risk of malignancy in oral LP. Modzatinib is a potential first-in-class oral therapy with a unique mechanism that inhibits both ITK and JAK3, potentially addressing LP at multiple points in its immune pathology. ITK inhibition blocks T-cell receptor signaling upstream, reducing T cell activation, CD8 T cell-mediated cytotoxicity, and inflammatory cytokine production, while JAK3 inhibition blocks downstream cytokine signaling to limit T cell proliferation, activation, and survival.
“We are excited to initiate the A LP HA trial, particularly given the unmet medical need in lichen planus and the mechanistic potential for modzatinib in this indication,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Modzatinib has demonstrated activity in multiple non-clinical disease models, including severe alopecia areata, vitiligo, and rheumatoid arthritis, as well as in a Phase 2a trial in atopic dermatitis with rapid and sustained improvements across clinical and patient-reported measures of disease severity, pruritus, and quality of life. This provides support for its continued development across immuno-inflammatory diseases. There are no FDA-approved therapies for people living with this debilitating disease, and we believe that modzatinib has the potential to be the first mechanistically complete oral therapy in this setting.”
The A LP HA trial is a randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of modzatinib at two dose levels compared with placebo in approximately 100 participants with biopsy-proven, moderate-to-severe LP not adequately controlled with topical therapies. The trial is designed to include three patient cohorts: oral erosive lichen planus, cutaneous lichen planus (CLP), and lichen planopilaris (LPP). The primary endpoints are change from baseline in activity score of the Oral Disease Severity Score (ODSS) at Week 16 (OLP), modified Lichen Planus Area and Severity Index (LPASI) score at Week 16 (CLP), and Lichen Planopilaris Activity Index (LPPAI) score at Week 24 (LPP). A variety of secondary and exploratory endpoints will also be assessed.
Select Upcoming Milestones
- Modzatinib : Top line results from the OLP cohort are expected in the second half of 2027.
- ATI-9494 (ITK/TXK inhibitor): Aclaris expects to file the IND this quarter. The planned Phase 1 clinical program will evaluate single (SAD) and multiple ascending doses (MAD) of ATI-9494 followed by a proof-of-concept portion in an undisclosed indication. The Company expects to initiate the trial in the first quarter of 2027.
-
ATI-052
(anti-TSLP/IL-4Rα bispecific antibody): Following the recent positive primary analysis results from Phase 1b proof-of-concept trials (press release
here
), Aclaris expects to prioritize the development of this molecule in eosinophilic esophagitis (EoE). The Company intends to initiate the Phase 2b trial of ATI-052 in EoE in the first quarter of 2027.
About Modzatinib (ATI-2138)
Modzatinib is a highly potent and selective novel investigational pharmacologic agent that acts as a dual inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3). ITK regulates T cell receptor signal transduction and inhibition of this kinase can affect T cell differentiation and activation. JAK3 is a key signal transduction kinase that forms a heterodimer with JAK1, modulates JAK1 phosphorylation of signal transducer and activator of transcription 5 (STAT5), and regulates cytokines that signal through the IL-2Rγ c to affect lymphocyte proliferation and activation. The results observed in preclinical animal models of inflammation and autoimmune diseases, coupled with the favorable safety, pharmacokinetics, and pharmacodynamics profile in healthy human studies and a Phase 2a trial in atopic dermatitis, support the potential for modzatinib to be the first mechanistically complete oral therapy for a variety of immuno-inflammatory disorders.
About Lichen Planus
Lichen planus (LP) is a chronic, immune-mediated inflammatory disease that can affect the mucous membranes, genitalia, skin, nails, and scalp. It is estimated to affect approximately 0.1% to 2% of the global population; up to 40% of patients seek treatment despite no FDA-approved targeted therapeutic interventions. Disease management is currently focused on immunosuppression and topical symptom control. When LP affects the mouth, it can cause painful burning sores, and erosive forms can make eating, drinking, and oral hygiene difficult; there is a malignancy concern with OLP. Common symptoms of cutaneous LP include severely itchy, flat-topped bumps or scales that often appear on the wrists, ankles, and lower back. LP can also lead to nail changes, scarring and permanent hair loss (lichen planopilaris), and painful genital lesions. Lichen planus can significantly affect a patient’s quality of life, with symptoms such as chronic itch, pain, and discomfort contributing to sleep disturbance, emotional distress, anxiety, depression, and limitations in daily activities.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn .
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its development plans for modzatinib, ATI-052 and ATI-9494, including its plans to evaluate modzatinib in OLP, CLP and LPP and the timing of top line results, the plans for and timing of initiating an EoE trial for ATI-052, and the plans for and timing of filing an IND, initiating a Phase 1 program for ATI-9494, and the potential therapeutic benefits of modzatinib, including the potential for modzatinib to be a mechanistically complete oral therapy for LP and other immuno-inflammatory disorders. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, top line and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]